Kurt Gunter | Clinical Development Advisor
Steminent Biotherapeutics Inc.

Kurt Gunter, MD, FASCP is a Clinical Development Advisor for Steminent Biotherapeutics and is also Chief Medical Officer at Inozyme Pharma. Kurt has over 30 years of expertise in regulatory affairs and clinical development, focusing on rare diseases and cell and gene therapy. Kurt was previously chief medical officer for cell therapy at Athenex, and chief medical officer at Kuur Therapeutics (formerly Cell Medica), where he headed the medical affairs, clinical operations, and regulatory affairs departments. He also previously held positions of increasing responsibility at Hospira, Inc., including vice president, clinical development, and global medical director for hematology-oncology. Before Hospira, Dr. Gunter held positions at ViaCell, and Transkaryotic Therapies, Inc. He also previously served as president of the International Society for Cellular Therapy (ISCT), where he played a worldwide leadership role in promoting understanding of the clinical, regulatory, manufacturing, and marketing requirements for the successful development of cell and gene therapies. Prior to his biotech career, Dr. Gunter worked at the U.S. Food and Drug Administration (FDA) as a medical officer in the Center for Biologics and was appointed deputy director of the Division of Cell and Gene Therapy within the Center for Biologics Evaluation and Research. He also served for five years on the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee. Dr. Gunter earned his M.D. from the University of Kansas School of Medicine, and has a B.S. in Biological Sciences, with Distinction, from Stanford University. His postdoctoral training included Johns Hopkins University and the U.S. National Institutes of Health.